Novo Nordisk has made history by getting the first FDA approval for a weight loss pill that works like the popular injectable drugs. This new pill, called oral Wegovy (semaglutide), is for people who are obese or overweight with health problems related to their weight. It’s also meant to lower the risk of serious heart problems in adults with heart disease who are overweight or obese. The pill will be available in early January 2026, and it’s already being made at Novo Nordisk’s facilities in North Carolina. The starting dose will cost about $149 per month. Novo Nordisk’s stock price went up by 5% after the FDA approval. This pill is different from the injectable Wegovy because it’s taken by mouth, which might make it easier for people to use. A recent study showed that people taking this pill, along with eating less and exercising, lost about 17% of their weight on average, compared to about 3% with a placebo. Novo Nordisk is hoping this new pill will help them compete with their main rival, Eli Lilly, whose weight loss drug, Zepbound, has been selling very well. Eli Lilly is also working on a similar pill, but it’s not approved yet. Novo Nordisk is waiting for FDA approval on a higher dose of their injectable Wegovy, which could help them stay ahead in the market.